Research > Transcription & Gene Targeting (Levon Khachigian)
Transcription and Gene Targeting
Group Leader: Professor Levon Khachigian
Overview of Research
Cardiovascular disease and cancer remain the most prevalent causes of morbidity and mortality. The pathogenesis of these and a myriad of related diseases is underpinned by molecular and cellular changes in our blood vessels. Professor Levon Khachigian’s research is uncovering key networks of transcriptional control and inducible gene-regulatory circuits that lead to vascular disease. The group is also developing new experimental drugs that have the potential to treat a diverse range of health problems, from cancer and inflammation through to eye and heart disease.
Professor Khachigian’s research program has two major objectives:
- To better understand how harmful genes are controlled in vascular cells. This arm investigates signaling and transcriptional mechanisms of pro-inflammatory cytokine-dependent gene expression, post-translational mechanisms that modify protein behavior, proteinase control, the isolation and characterization of new genes induced or repressed by vascular cell injury, and the molecular control of vascular cell migration and proliferation. The group has considerable expertise in animal models of neointima formation, angiogenesis, tumor growth, myocardial ischemia, and inflammation.
- To develop new vascular therapeutic agents. The lab is harnessing the outcomes of its fundamental research by pioneering the development of novel “anti-gene-” and “gene-therapeutic” strategies targeting key regulatory genes in a myriad of vascular disorders. This involves strategic collaborations with a range of clinical specialists, academics and drug development consultants. Khachigian has laid the framework for groundbreaking clinical trials translating the lab's discovery science into clinical “smart drug molecular assassin” technology. "First-in-man" trials of catalytic DNA molecules (DNAzymes) targeting key immediate-early genes will commence in Sydney in patients with skin cancer in 2010.
PhD and Hons projects are available in both these research streams in Khachigian Lab in 2010. If you’re interested, please email ,
sending your CV.
DNAzymes targeting c-Jun inhibit bone erosion in the collagen-antibody inducible arthritis (CAIA) model. Arrows denote bone-resorbing osteoclasts.
(Fahmy, R., Waldman, A., Zhang, G., Mitchell, A., Tedla, N., Cai, H., Chesterman, C.N., Geczy, C.R., Perry, M.A., Khachigian, L.M. (2006) Nature Biotech 24, 856-863)
Group Members
| Professor Levon Khachigian | Group Leader |
| Dr Lionel Lourenco-Dias | Post-doctoral Fellow (NHMRC-INSERM Fellow) |
| Dr Mary Kavurma | Post-doctoral Fellow (NHMRC CJ Martin Fellow) |
| Dr Jian-mei Li | Post-doctoral Fellow (UNSW Vice Chancellor’s Fellow) |
| Dr Hong Cai | Post-doctoral Fellow |
| Dr Mary Liu | Post-doctoral Fellow |
| Dr Kristine Malabanan | Post-doctoral Fellow |
| Dr Ying Morgan | Post-doctoral Fellow |
| Dr Bo Wang | Post-doctoral Fellow |
| Saadah Azahri | PhD student |
| Cecilia Chan | PhD student |
| Jeffrey Chan | PhD student |
| David Li | PhD student |
| Jun Ni | PhD student |
| Estella Sanchez-Guerrero | PhD student |
| Fernando Santiago | PhD student |
| Ning Zhang | PhD student |
| Elya | BSc(Hons) student |
| Margaret Patrikakis | Senior Research Assistant |
| Muhammad Zamil Mahmood Mattar | Research Assistant |
| Annie Au-Yeung | Research Assistant |
| Vicki Freeman | Personal Assistant (part-time) |
Key Publications
To view key publications from the Khachigian Lab,
click here.
Funding Sources